Skip to Content

New Drug Approvals Archive - December 2002

Get news by email or subscribe to our news feeds.

December 2002

December 2

Lexapro (escitalopram oxalate)

New Dosage Form Approved: November 27, 2002

December 18

Lexapro (escitalopram oxalate)

New Indication Approved: December 18, 2002

December 31

Humira (adalimumab) Injection

Date of Approval: December 31, 2002
Company: Abbott
Treatment for: Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease -- Acute, Crohn's Disease -- Maintenance, Psoriasis, Juvenile Idiopathic Arthritis, Ulcerative Colitis

Humira (adalimumab) is a recombinant human IgGl monoclonal antibody specific for human tumor necrosis factor (TNF) indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, juvenile idiopathic arthritis, and ulcerative colitis.

October 4

Humira (adalimumab)

New Indication Approved: October 3, 2005

July 31

Humira (adalimumab)

New Indication Approved: July 31, 2006

February 27

Humira (adalimumab)

New Indication Approved: February 27, 2007

January 22

Humira (adalimumab)

New Indication Approved: January 18, 2008

February 22

Humira (adalimumab)

New Indication Approved: February 21, 2008

September 28

Humira (adalimumab)

New Indication Approved: September 28, 2012

September 25

Humira (adalimumab)

Patient Population Altered: September 23, 2014

July 31

Finacea (azelaic acid)

New Dosage Form Approved: July 29, 2015